Is MIST or NGNE more profitable?

Neurogene's return on equity of -37.88% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Milestone Pharmaceuticals N/A -339.33% -61.79% Neurogene N/A -37.88% -34.70%

Does the media prefer MIST or NGNE?

In the previous week, Milestone Pharmaceuticals had 1 more articles in the media than Neurogene. MarketBeat recorded 2 mentions for Milestone Pharmaceuticals and 1 mentions for Neurogene. Milestone Pharmaceuticals' average media sentiment score of 1.51 beat Neurogene's score of 0.89 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Neurogene 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MIST or FBRX more profitable?

Forte Biosciences' return on equity of -106.17% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Milestone Pharmaceuticals N/A -339.33% -61.79% Forte Biosciences N/A -106.17% -85.50%

Does the media favor MIST or FBRX?

In the previous week, Forte Biosciences had 2 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 4 mentions for Forte Biosciences and 2 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 1.51 beat Forte Biosciences' score of 0.73 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Forte Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer AVTE or MIST?

Milestone Pharmaceuticals has a consensus price target of $7.25, indicating a potential upside of 517.02%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Milestone Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Is AVTE or MIST more profitable?

Aerovate Therapeutics' return on equity of -90.19% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Aerovate Therapeutics N/A -90.19% -77.47% Milestone Pharmaceuticals N/A -339.33% -61.79%

Is IMMX or MIST more profitable?

Immix Biopharma's return on equity of -73.24% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -73.24% -59.20% Milestone Pharmaceuticals N/A -339.33% -61.79%

Does the media refer more to IMMX or MIST?

In the previous week, Immix Biopharma and Immix Biopharma both had 2 articles in the media. Immix Biopharma's average media sentiment score of 1.68 beat Milestone Pharmaceuticals' score of 1.51 indicating that Immix Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Milestone Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to DNA or MIST?

In the previous week, Ginkgo Bioworks had 2 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 4 mentions for Ginkgo Bioworks and 2 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 1.51 beat Ginkgo Bioworks' score of 0.00 indicating that Milestone Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Milestone Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Milestone Pharmaceuticals (MIST) Competitors

$1.18 -0.01 (-0.84%)

As of 03:50 PM Eastern

Compare

MIST vs. NGNE, FBRX, AVTE, IMMX, and DNA

Should you buy Milestone Pharmaceuticals stock or one of its competitors? MarketBeat compares Milestone Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Milestone Pharmaceuticals include Neurogene (NGNE), Forte Biosciences (FBRX), Aerovate Therapeutics (AVTE), Immix Biopharma (IMMX), and Ginkgo Bioworks (DNA). These companies are all part of the "pharmaceutical products" industry.

How does Milestone Pharmaceuticals compare to Neurogene?

Milestone Pharmaceuticals (NASDAQ:MIST) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

In the previous week, Milestone Pharmaceuticals had 1 more articles in the media than Neurogene. MarketBeat recorded 2 mentions for Milestone Pharmaceuticals and 1 mentions for Neurogene. Milestone Pharmaceuticals' average media sentiment score of 1.51 beat Neurogene's score of 0.89 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Milestone Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Milestone Pharmaceuticals has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Neurogene has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market.

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 11.7% of Neurogene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Milestone Pharmaceuticals currently has a consensus price target of $7.25, suggesting a potential upside of 517.02%. Neurogene has a consensus price target of $84.83, suggesting a potential upside of 129.58%. Given Milestone Pharmaceuticals' higher possible upside, research analysts clearly believe Milestone Pharmaceuticals is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

Neurogene's return on equity of -37.88% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%
Neurogene	N/A	-37.88%	-34.70%

Milestone Pharmaceuticals has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	94.38	-$63.06M	-$0.68	N/A
Neurogene	$930K	627.79	-$90.35M	-$4.55	N/A

Summary

Milestone Pharmaceuticals beats Neurogene on 8 of the 15 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Forte Biosciences?

Milestone Pharmaceuticals (NASDAQ:MIST) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

Milestone Pharmaceuticals has higher revenue and earnings than Forte Biosciences. Forte Biosciences is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	94.38	-$63.06M	-$0.68	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Milestone Pharmaceuticals has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.85, meaning that its share price is 185% more volatile than the broader market.

Forte Biosciences' return on equity of -106.17% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%
Forte Biosciences	N/A	-106.17%	-85.50%

In the previous week, Forte Biosciences had 2 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 4 mentions for Forte Biosciences and 2 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 1.51 beat Forte Biosciences' score of 0.73 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Milestone Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Forte Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Milestone Pharmaceuticals presently has a consensus target price of $7.25, suggesting a potential upside of 517.02%. Forte Biosciences has a consensus target price of $67.00, suggesting a potential upside of 39.72%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Milestone Pharmaceuticals is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Milestone Pharmaceuticals beats Forte Biosciences on 11 of the 14 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

Milestone Pharmaceuticals has a consensus price target of $7.25, indicating a potential upside of 517.02%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by company insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Aerovate Therapeutics' return on equity of -90.19% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%

In the previous week, Milestone Pharmaceuticals had 2 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 2 mentions for Milestone Pharmaceuticals and 0 mentions for Aerovate Therapeutics. Milestone Pharmaceuticals' average media sentiment score of 1.51 beat Aerovate Therapeutics' score of 0.00 indicating that Milestone Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
Milestone Pharmaceuticals	Very Positive

Milestone Pharmaceuticals has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Milestone Pharmaceuticals	$1.55M	94.38	-$63.06M	-$0.68	N/A

Summary

Milestone Pharmaceuticals beats Aerovate Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Immix Biopharma?

Immix Biopharma (NASDAQ:IMMX) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Immix Biopharma presently has a consensus price target of $20.67, suggesting a potential upside of 132.08%. Milestone Pharmaceuticals has a consensus price target of $7.25, suggesting a potential upside of 517.02%. Given Milestone Pharmaceuticals' higher possible upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Immix Biopharma and Immix Biopharma both had 2 articles in the media. Immix Biopharma's average media sentiment score of 1.68 beat Milestone Pharmaceuticals' score of 1.51 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Milestone Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Immix Biopharma has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by company insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Immix Biopharma's return on equity of -73.24% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-73.24%	-59.20%
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%

Immix Biopharma has higher earnings, but lower revenue than Milestone Pharmaceuticals. Immix Biopharma is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A
Milestone Pharmaceuticals	$1.55M	94.38	-$63.06M	-$0.68	N/A

Summary

Milestone Pharmaceuticals beats Immix Biopharma on 7 of the 13 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

In the previous week, Ginkgo Bioworks had 2 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 4 mentions for Ginkgo Bioworks and 2 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 1.51 beat Ginkgo Bioworks' score of 0.00 indicating that Milestone Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Milestone Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Ginkgo Bioworks has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Milestone Pharmaceuticals has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Ginkgo Bioworks' return on equity of -56.08% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%

Ginkgo Bioworks presently has a consensus price target of $8.50, indicating a potential upside of 11.92%. Milestone Pharmaceuticals has a consensus price target of $7.25, indicating a potential upside of 517.02%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Milestone Pharmaceuticals has lower revenue, but higher earnings than Ginkgo Bioworks. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	2.92	-$312.76M	-$5.36	N/A
Milestone Pharmaceuticals	$1.55M	94.38	-$63.06M	-$0.68	N/A

78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by company insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Milestone Pharmaceuticals beats Ginkgo Bioworks on 10 of the 17 factors compared between the two stocks.

Get Milestone Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MIST vs. The Competition

Export

Metric	Milestone Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$146.29M	$3.64B	$6.80B	$12.31B
Dividend Yield	N/A	2.17%	2.67%	9.36%
P/E Ratio	-1.73	20.84	27.16	24.03
Price / Sales	94.38	302.97	573.71	113.02
Price / Cash	N/A	60.31	29.05	48.09
Price / Book	3.01	7.93	10.67	6.16
Net Income	-$63.06M	$23.81M	$3.59B	$331.63M
7 Day Performance	-8.20%	-1.69%	-1.46%	-1.53%
1 Month Performance	-9.89%	2.24%	1.20%	-1.24%
1 Year Performance	-25.63%	43.54%	24.36%	17.49%

Milestone Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MIST Milestone Pharmaceuticals	2.5234 of 5 stars	$1.18 -0.8%	$7.25 +517.0%	-25.0%	$146.29M	$1.55M	N/A	30
NGNE Neurogene	3.3263 of 5 stars	$38.32 -3.3%	$84.83 +121.4%	+67.0%	$626.23M	$930K	N/A	90
FBRX Forte Biosciences	2.2301 of 5 stars	$44.12 +0.5%	$67.00 +51.9%	+380.0%	$609.86M	N/A	N/A	5
AVTE Aerovate Therapeutics	N/A	$20.95 -6.8%	N/A	+120.3%	$607.24M	N/A	N/A	20	Gap Down High Trading Volume
IMMX Immix Biopharma	3.606 of 5 stars	$10.52 -5.3%	$20.67 +96.5%	+245.1%	$604.51M	N/A	N/A	9	News Coverage Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MIST) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Milestone Pharmaceuticals (MIST) Competitors

MIST vs. NGNE, FBRX, AVTE, IMMX, and DNA

How does Milestone Pharmaceuticals compare to Neurogene?

Summary

How does Milestone Pharmaceuticals compare to Forte Biosciences?

Summary

How does Milestone Pharmaceuticals compare to Aerovate Therapeutics?

Summary

How does Milestone Pharmaceuticals compare to Immix Biopharma?

Summary

How does Milestone Pharmaceuticals compare to Ginkgo Bioworks?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIST vs. The Competition

Milestone Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Milestone Pharmaceuticals (MIST) Competitors

MIST vs. NGNE, FBRX, AVTE, IMMX, and DNA

How does Milestone Pharmaceuticals compare to Neurogene?

Does the media prefer MIST or NGNE?

Which has more volatility and risk, MIST or NGNE?

Do insiders & institutionals hold more shares of MIST or NGNE?

Do analysts rate MIST or NGNE?

Is MIST or NGNE more profitable?

Which has stronger earnings and valuation, MIST or NGNE?

Summary

How does Milestone Pharmaceuticals compare to Forte Biosciences?

Which has higher earnings & valuation, MIST or FBRX?

Do insiders and institutionals have more ownership in MIST or FBRX?

Which has more volatility and risk, MIST or FBRX?

Is MIST or FBRX more profitable?

Does the media favor MIST or FBRX?

Do analysts prefer MIST or FBRX?

Summary

How does Milestone Pharmaceuticals compare to Aerovate Therapeutics?

Do analysts prefer AVTE or MIST?

Do insiders and institutionals have more ownership in AVTE or MIST?

Which has more volatility and risk, AVTE or MIST?

Is AVTE or MIST more profitable?

Does the media refer more to AVTE or MIST?

Which has preferable earnings & valuation, AVTE or MIST?

Summary

How does Milestone Pharmaceuticals compare to Immix Biopharma?

Do analysts rate IMMX or MIST?

Does the media refer more to IMMX or MIST?

Which has more volatility & risk, IMMX or MIST?

Do institutionals and insiders hold more shares of IMMX or MIST?

Is IMMX or MIST more profitable?

Which has better earnings & valuation, IMMX or MIST?

Summary

How does Milestone Pharmaceuticals compare to Ginkgo Bioworks?

Does the media refer more to DNA or MIST?

Which has more risk & volatility, DNA or MIST?

Is DNA or MIST more profitable?

Do analysts recommend DNA or MIST?

Which has preferable earnings and valuation, DNA or MIST?

Do institutionals and insiders believe in DNA or MIST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIST vs. The Competition

Milestone Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools